Highline Wealth Partners LLC Buys Shares of 40,601 Pfizer Inc. (NYSE:PFE)

Highline Wealth Partners LLC purchased a new position in Pfizer Inc. (NYSE:PFE) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 40,601 shares of the biopharmaceutical company’s stock, valued at approximately $1,175,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. LGT Group Foundation lifted its holdings in shares of Pfizer by 2.5% during the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after buying an additional 18,274 shares during the last quarter. Creative Planning lifted its stake in Pfizer by 17.1% in the third quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock valued at $52,692,000 after acquiring an additional 266,167 shares during the last quarter. ORG Partners LLC grew its position in Pfizer by 1,729.9% in the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after acquiring an additional 44,458 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in shares of Pfizer by 10.3% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 256,460 shares of the biopharmaceutical company’s stock worth $7,422,000 after purchasing an additional 23,928 shares during the last quarter. Finally, Everett Harris & Co. CA lifted its stake in shares of Pfizer by 21.7% in the 3rd quarter. Everett Harris & Co. CA now owns 218,344 shares of the biopharmaceutical company’s stock valued at $6,319,000 after purchasing an additional 38,870 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of Pfizer stock opened at $28.31 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a market cap of $160.42 billion, a PE ratio of -61.89, a price-to-earnings-growth ratio of 0.99 and a beta of 0.67. The firm has a fifty day moving average price of $29.07 and a two-hundred day moving average price of $28.56. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) earnings per share. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.93%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is presently -365.21%.

Analyst Ratings Changes

Several equities analysts have commented on PFE shares. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, UBS Group upped their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.